Navigation Links
BioMS Medical Announces Third Quarter 2008 Results
Date:11/6/2008

g dirucotide

(MBP8298) for the treatment of SPMS. The trial is fully recruited

with approximately 510 patients enrolled at 68 sites across the U.S.

To date, the DSMB has conducted three reviews of the data from this

trial and has recommended it continue.

- MINDSET-01: A phase II clinical trial evaluating dirucotide (MBP8298)

for the treatment of relapsing-remitting MS (RRMS). The randomized,

double-blind study has completed recruitment with 218 patients

enrolled at 24 trial sites in six countries across Europe. The DSMB

has completed six safety reviews to date and recommended that the

trial continue as per the protocol. Completion of the double-blind

phase of the trial is expected at the end of 2008 with results

anticipated in the first quarter of 2009.

Financial Results

The consolidated net income for the three months ended September 30, 2008 was $6.3 million or $0.07 per share compared with a net loss of $10.9 million or ($0.12) per share for the three months ended September 30, 2007. The consolidated net loss for the nine months ended September 30, 2008 was $0.8 million or ($0.01) per share compared with a loss of $35.5 million or ($0.43) per share for the same period in 2007.

Revenue for the three months ended September 30, 2008 was $16.1 million compared to $nil for the same period of 2007. Revenue for the nine months ended September 30, 2008 was $40.1 million compared to $nil for the same period of 2007. The revenue is the result of recognizing a portion of the upfront payment and development milestone for the positive interim analysis related to the MAESTRO-01 clinical trial received from the licensing agreement with Lilly.

Total consolidated expenses for the three months ended September 30, 2008 were $11.8 million compared to $10.6 million for the same period of 2007. Total consolidated expenses for the nine months
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , September 2, 2015 BiondVax Pharmaceuticals ... the National Institute of Allergy and Infectious Diseases (NIAID), part ... Department of Health and Human Services (HHS), to launch a ... the United States in the 2015-16 timeframe. The ... candidate, Multimeric-001 (M-001), as a primer vaccine, which would be ...
(Date:9/2/2015)... ... September 02, 2015 , ... Whitehouse Laboratories is excited ... Pharma Ed Resources upcoming educational seminar and training session on Extractable & Leachable ... conference will provide Updates & Case Studies on the Latest Compliance Implications of ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... science research, today unveiled Genedata Screener ® version 13.0 at ELRIG Drug ... brings to market a rich set of new capabilities. Screener now supports High ...
(Date:9/1/2015)... , Sept. 1, 2015 The American ... Intent (LOI) for its Discovery Research Grant program. LOIs ... at 12:00 noon CDT. Discovery Grants ... with the potential to change current diagnostic or treatment ... grants specifically encourage novel research at its earliest stages, ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2
... Lentigen Corporation announced today,that it has received ... research (SBIR) grants to collaborate with leading,scientists. Through ... (LV) technology to the development of novel,immunotherapeutic treatments ... -- Melanoma, with Michael Nishimura, Ph.D, Associate ...
... 15 Baxa Corporation, a,Denver-based manufacturer of medical ... Marketing Association Gold Key Awards for its,integrated direct ... Colorado,s most highly acclaimed marketing competitions, the BMA,Gold ... on May 3rd at the,Cable Center at the ...
... a leading life sciences company, announced today that the ... Executive Officer,and a member of the Cambrex Corporation Board ... and Chief Executive Officer since 1995,and Chairman since 1999, ... the positions of Board Chairman and CEO and John ...
Cached Biology Technology:Lentigen Corporation Receives Four Research Grants From the National Institutes of Health 2Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards 2Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards 3Cambrex Appoints Steven M. Klosk as President and CEO 2
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
(Date:8/5/2015)... August 5, 2015 Transparency Market ... Recognition Market - Global Industry Analysis, Size, Share, Growth, ... for facial recognition is forecast to reach US$ 2,671.8 ... demand for surveillance systems by civil and government agencies. ... crimes and terrorist activities across the globe that would ...
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... retailer of wine products, BRSM Sales LLC, today announced the ... holiday shopping: www.GreatWineProducts.com . The new ... products including but not limited to: glass and stemware, burlap ... In addition to personal use, many items make ...
... the fight against pneumonia is the focus of ... University ePress., With an aim to establish an ... ,is a peer-reviewed, open-access journal which brings together ... Griffith,s Professor Allan Cripps is the Editor in ...
... 2013 New data suggest that the transcription ... Researchers determined that alcohol given to mice deficient ... alcoholic hepatitis. Further they found that although hepatitis ... in combination they suppressed FOXO3, reduced expression of ...
Cached Biology News:Griffith joins the fight against pneumonia 2Transcription factor may protect against hepatic injury caused by hepatitis C and alcohol 2Transcription factor may protect against hepatic injury caused by hepatitis C and alcohol 3
... uptake of long double stranded RNA (dsRNA) ... in a diverse group of organisms as ... interference leads to the inhibition of protein ... the target messenger RNA (mRNA). Attempts to ...
... Powerful exact mass measurements in ... orthogonal electrospray time-of-flight mass spectrometer (ESI-oa-TOF) ... machine in a format, which fits ... a mass resolution exceeding 10,000 FWHM ...
... Performance The TSQ Quantum Ultra defines ... bioanalytical and environmental analysis. It features ... APCI probes, a titanium skimmer with superior ... and sensitivity. Its redesigned ion transfer ...
... of long double stranded RNA (dsRNA) has ... a diverse group of organisms as well ... leads to the inhibition of protein expression ... target messenger RNA (mRNA). Attempts to induce ...
Biology Products: